Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages 2556-2564

  Boige, Valérie ^a   Mendiboure, Jean ^a   Pignon, Jean Pierre ^a   Loriot, Marie Anne ^a   Castaing, Marine ^a   Barrois, Michel ^a   Malka, David ^a   Trégouët, David Alexandre ^a   Bouché, Olivier ^a   Le Corre, Delphine ^a   Miran, Isabelle ^a   Mulot, Claire ^a   Ducreux, Michel ^a   Beaune, Philippe ^a   Laurent Puig, Pierre ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IRINOTECAN; OXALIPLATIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAZARD RATIO; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TOXICITY; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956398850     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.2106     Document Type: Article

References (52)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000 (Pubitemid 30644117)
2. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
3. Seymour MT, Maughan TS, Ledermann JA, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370:143-152, 2007 (Pubitemid 47042894)
4. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370:135-142, 2007 (Pubitemid 47042893)
5. Kawakami K, Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63:6004-6007, 2003 (Pubitemid 37187503)
6. Mandola MV, Stoehlmacher J, Zhang W, et al: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319-327, 2004 (Pubitemid 38638919)
7. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5FU chemotherapy. Pharmacogenomics J 1:65-70, 2001 (Pubitemid 33757985)
8. Jakobsen A, Nielsen JN, Gyldenkerne N, et al: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23:1365-1369, 2005
9. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113, 1995
10. Weisberg I, Tran P, Christensen B, et al: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decrease enzyme activity. Mol Genet Metab 64: 169-172, 1998 (Pubitemid 28453294)
11. Etienne MC, Ilc K, Formento JL, et al: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: Relationships with 5-fluorouracil sensitivity. Br J Cancer 90:526-534, 2004 (Pubitemid 38250655)
12. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320, 2005 (Pubitemid 41130944)
13. Viguier J, Boige V, Miquel C, et al: ERCC1 codon 118 polymorphism is a predictive factor for the tumor responsetooxaliplatin/5- fluorouracilcombinationchemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11:6212-6217, 2005 (Pubitemid 41262950)
14. Park DJ, Stoehlmacher J, Zhang W, et al: A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654-8658, 2001 (Pubitemid 34013872)
15. Stoehlmacher J, Park DJ, Zhang, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936-942, 2002 (Pubitemid 34778092)
16. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002 (Pubitemid 34982202)
17. Hoskins JM, Goldberg RM, Qu P, et al: UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 99:1290-1295, 2007 (Pubitemid 47394168)
18. Côté JF, Kirzin S, Kramar A, et al: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269-3275, 2007 (Pubitemid 46944912)
19. Bouché O, Castaing M, Etienne PL, et al: Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): Preliminary results. J Clin Oncol 25:180s, 2007 (suppl; abstr 4069)
20. Leonard P, Seymour MT, James R, et al: Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 87:1216-1220, 2002 (Pubitemid 36009125)
21. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
22. Tregouet DA, Escolano S, Tiret L, et al: A new maximum likelihood algorithm for haplotype-based association analysis: The SEM algorithm. Ann Hum Genet 68:165-177, 2004 (Pubitemid 38379847)
23. Meta-Analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541, 1998
24. Köhne CH, Cunningham D, Di Costanzo F, et al: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3,825 patients. Ann Oncol 13:308-317, 2002 (Pubitemid 34704985)
25. Lecomte T, Ferraz JM, Zinzindohoué F, et al: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880-5888, 2004 (Pubitemid 39180969)
26. Schwab M, Zanger UM, Marx C, et al: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5FU Toxicity Study Group. J Clin Oncol 26:2131-2138, 2008
27. Ducreux M, Bouche O, Pignon JP, et al: Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer: Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. Oncology 70:222-230, 2006 (Pubitemid 44154696)
28. Lecomte T, Landi B, Beaune P, et al: Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12:3050-3056, 2006 (Pubitemid 43837350)
29. Goekkurt E, Al-Batran SE, Hartmann JT, et al: Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 27:2863-2873, 2009
30. Ruzzo A, Graziano F, Loupakis F, et al: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:1247-1254, 2007 (Pubitemid 46640571)
31. Lunn RM, Helzlsouer KJ, Parshad R, et al: XPD polymorphisms: Effects on DNA repair proficiency. Carcinogenesis 21:551-555, 2000 (Pubitemid 30214005)
32. Benhamou S, Sarasin A: ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 17: 463-469, 2002 (Pubitemid 35414774)
33. Pastorelli R, Cerri A, Mezzetti M, et al: Effect of DNA repair gene polymorphisms on BPDE-DNA adducts in human lymphocytes. Int J Cancer 100:9-13, 2002 (Pubitemid 34602058)
34. Marsh S, McKay JA, Cassidy J, et al: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19:383-386, 2001
35. Etienne MC, Chazal M, Laurent-Puig P, et al: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: Phenotypic and genotypic analyses. J Clin Oncol 20:2832-2843, 2002 (Pubitemid 34651512)
36. Morganti M, Ciantelli M, Giglioni B, et al: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41:2176-2183, 2005 (Pubitemid 41337961)
37. Marcuello E, Altes A, del Rio E, et al: Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112:733-737, 2004 (Pubitemid 39435256)
38. Graziano F, Ruzzo A, Loupakis F, et al: Liveronly metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. Br J Cancer 99:716-721, 2008
39. Etienne-Grimaldi MC, Formento JL, Francoual M, et al: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 14:4830-4835, 2008
40. Etienne MC, Formento JL, Chazal M, et al: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14:785-792, 2004 (Pubitemid 40054334)
41. Etienne-Grimaldi MC, Milano G, Maindrault- Goebel F, et al: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69:58-66, 2010
42. Raymond E, Chaney SG, Taamma A, et al: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9:1053-1071, 1998 (Pubitemid 28518143)
43. Stoehlmacher J, Park DJ, Zhang W, et al: A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354, 2004 (Pubitemid 39037082)
44. Xiao Z, Yang L, Xu Z, et al: Glutathione S-transferases (GSTT1 and GSTM1) genes polymorphisms and the treatment response and prognosis in Chinese patients with de novo acute myeloid leukemia. Leuk Res 32:1288-1291, 2008 (Pubitemid 351626919)
45. Davies SM, Robison LL, Buckley JD, et al: Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 19:1279-1287, 2001 (Pubitemid 32202531)
46. Howells RE, Redman CW, Dhar KK, et al: Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res 4:2439-2445, 1998 (Pubitemid 28477910)
47. Voso MT, D'Alo F, Putzulu R, et al: Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 100:2703-2707, 2002
48. Ekhart C, Rodenhuis S, Smits PH, et al: An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 35:18-31, 2009
49. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54:4313-4320, 1994
50. Ishikawa T, Ali-Osman F: Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells: Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268:20116-20125, 1993 (Pubitemid 23278910)
51. Hitre E, Budai B, Adleff V, et al: Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 15:723-730, 2005 (Pubitemid 41345324)
52. Dotor E, Cuatrecases M, Martínez-Iniesta M, et al: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24:1603-1611, 2006 (Pubitemid 46638784)